Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer

Video

In Partnership With:

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

Leigha Senter, MS, LGC, associate professor, Division of Human Genetics, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

There are a number of other gene alterations that carry an increased risk of developing cancer, says Senter. These mutations can help shed light on the origin of the cancer, and can indicate whether further testing for other cancers should be considered. Also, they can guide screening and treatment interventions for family members who may be at risk.

Further investigation with these mutations may lead to additional targeted therapies, concludes Senter.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD